|
|
 |
|
Biosyn submits IND application for novel HIV microbicide Biosyn release Biosyn, Inc. announced that the company has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) for the development of UC-781 as an HIV microbicide. Biosyn plans to initiate clinical trials investigating UC-781’s safety, and later efficacy, as a microbicide to prevent sexual transmission of HIV. UC-781 is an HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) that has shown in vitro to be very active specifically against HIV-1. UC-781’s mechanism of action is inactivation of reverse transcriptase, an enzyme involved in HIV replication within human cells.
—Posted: July 2, 2003
More news headlines: This week | Last week | Search archive
|
|
|
